Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LQDA
HoldPremium GrowerLiquidia Corporation · Healthcare · United States · $6.1B · Avg Vol: $98M/d
COMPANY DESCRIPTION
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing innovative therapies using its proprietary PRINT® technology, which precisely controls particle size and shape for drug delivery. This advanced technology provides a significant competitive edge by enabling improved drug efficacy and patient outcomes for conditions like pulmonary arterial hypertension. Liquidia is a niche player aiming to disrupt existing treatment paradigms with novel formulations.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 15.9M | 17.5M | 14.0M | 158.3M | 115.0% | 450.9M | 738.9M | 1.2B | 178.2% |
| EPS | -0.70 | -0.67 | -1.21 | -1.66 | -0.80 | — | 1.40 | — | — | — |
| Shares | — | 64.5M | 68.6M | 84.7M | 87.2M | +35.2% | 89.5M | — | — | — |
| Debt | — | 24.5M | 49.5M | 120.3M | 197.9M | 100.8% | 182.9M | — | — | — |
| Equity | — | 90.4M | 47.3M | 79.4M | 44.7M | -20.9% | — | — | — | — |
| Op CF | — | -28.6M | -41.6M | -93.4M | -35.7M | — | 167.7M | — | — | — |
| Inv CF | — | -0.6M | -11.3M | -8.4M | -6.3M | — | — | — | — | — |
| Fin CF | — | 65.0M | 43.2M | 194.7M | 59.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LQDA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LQDA | Liquidia Corporation(you) | $6.1B | 64 | Hold |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.1B | 83 | Strong Buy |
| ELAN | Elanco Animal Health Incorporated | $12.0B | 70 | Buy |
| PBH | Prestige Consumer Healthcare Inc. | $2.5B | 67 | Buy |
| LNTH | Lantheus Holdings, Inc. | $6.6B | 88 | Strong Buy |
| XERS | Xeris Biopharma Holdings, Inc. | $1.5B | 60 | Hold |
| CURA.TO | Curaleaf Holdings, Inc. | $2.6B | 48 | Hold |
| ETON | Eton Pharmaceuticals, Inc. | $1.7B | 72 | Buy |
| ZTS | Zoetis Inc. | $32.0B | 66 | Buy |
| PAHC | Phibro Animal Health Corporation | $1.5B | 74 | Buy |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.1%